NASDAQ:ATHX

Athersys (ATHX) Stock Price, News & Analysis

Athersys logo

About Athersys Stock (NASDAQ:ATHX)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2 shs
Average Volume
1.77 million shs
Market Capitalization
$833 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Athersys, Inc. was a Cleveland-based biotechnology company focused on regenerative medicine and cell therapies for serious medical conditions. Founded in 1995, the company developed investigational treatments rather than marketed products.

Its leading program was MultiStem, an off-the-shelf cell therapy made from multipotent adult progenitor cells. Athersys studied MultiStem in clinical trials for conditions including ischemic stroke and acute respiratory distress syndrome; it was not an approved commercial treatment.

Athersys collaborated with Japan-based Healios on the development of MultiStem. After Athersys filed for Chapter 11 bankruptcy protection in 2023, Healios acquired substantially all of the company’s assets related to the program.

AI Generated. May Contain Errors.

Receive ATHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATHX Stock News Headlines

Athersys to Sell Most Assets to Healios
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Athersys shares delisted by Nasdaq Stock Market
Athersys crashes after bankruptcy warning
See More Headlines

ATHX Stock Analysis - Frequently Asked Questions

Athersys, Inc. (NASDAQ:ATHX) released its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($1.75) EPS for the quarter, beating the consensus estimate of ($2.00) by $0.25. The biopharmaceutical company had revenue of $4.79 million for the quarter.

Athersys's stock reverse split on Monday, August 29th 2022.The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Dynavax Technologies (DVAX), Bank of America (BAC), Novavax (NVAX) and Micron Technology (MU).

Company Calendar

Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ATHX
CIK
1368148
Employees
24
Year Founded
1995

Profitability

EPS (Trailing Twelve Months)
($2.03)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$72.53 million
Net Margins
N/A
Pretax Margin
-46,304.93%
Return on Equity
N/A
Return on Assets
-223.03%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.06
Quick Ratio
0.06

Sales & Book Value

Annual Sales
$146 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.33) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
61,719,000
Free Float
61,700,000
Market Cap
$833 thousand
Optionable
No Data
Beta
-0.90

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:ATHX) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners